Update in Dyslipidemias
-
Upload
kristopher-maday -
Category
Health & Medicine
-
view
31 -
download
1
Transcript of Update in Dyslipidemias
Update on Dyslipidemias
Kristopher Maday, MS, PA-C, CNSCUniversity of Alabama at Birmingham
Pegasus Emergency Group
Objectives• Review the different types of lipids that are
important for clinical practice• Discuss the cardiovascular risk scores• Describe current lifestyle modification
recommendations in the treatment of hyperlipidemia
• Evaluate the 2013 AHA/ACC guidelines for dyslipidemia management
• Appraise the pharmacologic treatment options for dyslipidemias
What are lipids?• Carbon and hydrogen containing compounds
that are insoluble in water, but are soluble in organic solvents
• Functions– Sources of energy– Formation of cell membrane– Constitute bile acids
• Derived from both dietary sources and internal body processes
Types of Plasma Lipids• Sterols
– Cholesterol• Neutral Fats
– Triglycerides– Free Fatty Acids
• Conjugated Lipids– Phospholipids– Lipoproteins
Cholesterol• Necessary for the formation of cell
membranes, bile salts, adrenocorticosteroids, estrogens, and androgens
• 75% is bound to LDL• Levels can fluctuate as much as 8%
during one day and 15% from day to day
Free Fatty Acids• Travel through
bloodstream combined with albumin
• Blood levels are never high unless stimulated to release fat– Same stimulus will also
elevate triglycerides• Utilized for energy in
muscle tissue
Triglycerides• Combination of 3 FFA and 1 glycerol
molecule• Main form of lipid storage• Used in the body to provide energy:
– Directly as a energy source– Indirectly for gluconeogenesis
• Transported by VLDL and LDL
Phospholipids• 3 main types
– Lecithins• Involved in pulmonary gas exchange
– Cephalins• Major constituent of thromboplastin
– Sphingomyelins• Involved with formation of myelin sheath in CNS
• Important for the formation of cell membrane and transportation of fatty acids through the intestinal mucosa into lymph
• Lecithin:Sphingomyelin ratio– Fetal lung maturation
Lipoproteins• Main function is to transport cholesterol and
triglycerides
• Grouped by density– Chylomicrons
• Primarily triglycerides– Very-Low Density Lipoprotein (VLDL)
• Mainly triglycerides– Low Density Lipoprotein (LDL)
• Primarily cholesterol– High Density Lipoprotein (HDL)
• Mainly protein with small amount of cholesterol
Very-Low Density Lipoprotein
• Predominant carrier of blood triglycerides
• High concentrations cause alterations of appearance of serum (ie. hazy, turbid)
• Associated with increased risk of CAD
Low Density Lipoprotein
• Very cholesterol rich• High association with CAD• ***Main focus of pharmacotherapy***• Friedewald Formula
– LDL = TC – (HDL + (triglycerides/5))
Lipoprotein CharacteristicsLipoprotein Size Density Major
Apolipoprotein Origins Comments
Chylomicron Largest Least ApoB-48 Intestines Primarily triglycerides
Very Low-Density
Lipoprotein(VLDL)
ApoB-100 Liver and Intestines Primarily triglycerides
Intermediate-density
Lipoprotein(IDL)
ApoB-100 Chylomicrons and VLDL
Transitional forms
Low-density Lipoprotein
(LDL)ApoB-100 End-product of VLDL Major carrier
of cholesterol
High-density Lipoproteins
(HDL)Smallest Most ApoA-1 Intestines and liver Removes
cholesterol
Lipoprotein Phenotyping• 6 different phenotypes of lipoproteins• Each phenotype has correlated with
genetically determined abnormalities as well as a variety of acquired conditions
• Useful in diagnosing and treating specific hyperlipoproteinemias
Physical Exam Findings• Majority of hypercholesterolemia
patients are diagnosed by laboratory abnormalities
• Extremely elevated LDL and triglycerides– Eruptive xanthomas
• Red-yellow papules– Tendinous xanthomas– Lipemia retinalis
• Cream-colored blood vessels in fundus
Eruptive Xanthomas
Tendinous Xanthoma
Lipemia Retinalis
Treatment
Lifestyle Modifications • Diet
– Decrease:• Total fat to 25-30% of calories
– Saturated fat < 7% of calories• Total cholesterol < 200 mg/dl
• Physical Activity– 150 minutes a week
• Weight loss– > 10% for overweight patients
Who Needs Pharmacotherapy?
• Clinical Atherosclerotic Cardiovascular Disease (ASCVD)– Acute Coronary Syndrome– Myocardial Infarction– Stable or Unstable Angina– Revascularization Procedures– Cerebrovascular Disease– Peripheral Arterial Disease
• LDL ≥ 190 mg/dL• Type I or II Diabetes AND age 40-75• 10-year ASCVD risk ≥ 7.5% AND age 40-75
Cardiovascular Risk Scores• Calculates a patient’s 10 year risk for a
major cardiovascular event– Framingham Score
• Age, Gender, Total cholesterol, HDL, SBP, Smoking
– Reynolds Score• Age, Smoking, SBP, Total Cholesterol, CRP, Family
History– PROCAM Score
• Age, Gender, DM, Smoking, Family History, SBP, BMI, Antihypertensive therapy
Statins: Mechanism of Action
LDL receptor–mediated hepatic uptake of LDL and VLDL remnants
Serum VLDL remnantsSerum LDL-C
Cholesterol synthesis
LDL receptor (B–E receptor) synthesis
Intracellular Cholesterol
Apo BApo E
Apo B
Systemic CirculationHepatocyteReduce hepatic cholesterol synthesis, lowering intracellular
cholesterol, which stimulates upregulation of LDL receptor and increases the uptake of non-HDL particles from the systemic
circulation.
LDL
Serum IDL
VLDLR
VLDL
Risk Reduction with Statin Therapy
Endpoints +20 –35–30–250 –5 –10–15–20Relative Risk Reduction (%)
–40–45–50
Major coronary eventsCoronary deathsCardiovascular deathsNoncardiovascular events
Total mortalityStrokesIntermittent claudicationAngina
Statin Adverse Events• Common side effects
- Headache – Myalgia – Fatigue- GI intolerance – Flu-like symptoms
• Increase in liver enzymes– Occurs in 0.5 to 2.5% of cases in dose-dependent manner– Serious liver problems are exceedingly rare– Manage by reducing statin dose or discontinue until levels return to
normal• Myopathy
– Occurs in 0.2 to 0.4% of patients– Rare cases of rhabdomyolysis– Reduce by
• Cautiously using statins in patients with impaired renal function• Using the lowest effective dose• Cautiously combining statins with fibrates• Avoiding drug interactions• Careful monitoring of symptoms
– Presence of muscle toxicity requires the discontinuation of the statin
Nicotinic Acid: Mechanism of Action
Liver CirculationHDL
Serum VLDL results in reduced lipolysis to LDL
Serum LDL
VLDL
Decreases hepatic production of VLDL and ApoB
VLDL secretion
Apo B
Hepatocyte Systemic Circulation
Mobilization of FFA
TG synthesis
VLDL
LDL
Nicotinic Acid• Products available (daily dose)
• Immediate-release, 2–4 g/d• Extended-release (Niaspan®), 1–2 g/d• OTC products, sustained-release, 2 g/d
• Best agent to raise HDL-C• Adverse effects
• Flushing, itching, headache (immediate-release, Niaspan®)
• Hepatotoxicity, GI (sustained-release)• Activation of peptic ulcer• Hyperglycemia and reduced insulin sensitivity
• Contraindications• Active liver disease or unexplained LFT elevations• Peptic ulcer disease
Bile Acid Resins: Mechanism of Action
Net Effect: LDL-C
Gall Bladder
LDL Receptors VLDL and LDL removal
Cholesterol 7- hydroxylase Conversion of cholesterol to BA BA Secretion
Liver
BA Excretion
Terminal Ileum
Bile AcidEnterohepatic Recirculation
Reabsorption of bile acids
Bile Acid Binding Resins• Products available:
• Cholestyramine (Questran), 4–16 g/d• Colestipol (Colestid), 5–20 g/d• Colesevelam (WelChol) 625 mg tablets, 6–7 tablets/d
• Reduce coronary events (LRC-CPPT)• Adverse effects
• GI intolerance: constipation, bloating, abdominal pain, flatulence
• Lack systemic toxicity• Drug interactions (colestipol and cholestyramine)
• Bind other negatively charged drugs• Impede the absorption of drugs and/or fat-soluble vitamins• Must give other drugs 1 hour before or 4–6 hours after
Fibric Acid Derivatives: Mechanism of Action
Fibric Acid Derivitives• Products available:
• Fenofibrate 48-160mg • Fenofibric acid 35-105mg• Gemfibrozil 600mg
• Adverse effects• GI side effects• Myositis• Abnormal liver function
• Contraindications• Hepatic or renal dysfunction• Pre-existing gall bladder disease
Duodenum
Jejunum
Ileum
CMapoB48
Liver
CM RemnantapoB48
VLDLapoB100
EzetimibeX
LDLapoB100
XStatin
Colon
Ezitimibe: Mechanism of Action
Omega-3 Fatty Acids• Lipid effect
– Reduced hepatic VLDL production• EPA (eicosapentaenoic acid) and DHA
(docosahexaenoic acid) in fish oils are more effective than alpha-linolenic acid in vegetable sources
• Doses >7g/day – decreased TG 25% and increased TC 2% in normal patients; – 28% and 7%, respectively, in HTG patients
• Omacor (85% omega-3 fatty acid ethyl esters) at 4g/day = 27-45% TG reduction
• Side Effects: fishy aftertaste
Conclusion• Encourage lifestyle modifications• Start statin pharmacotherapy if:
– (+) ASCVD– LDL > 190 mg/dL– 40-75yo AND:
• DM type I or II or • > 7.5% 10-year CV risk
• Tailor additional pharmacotherapy based on lipid panel